undamentalytics Newsletter
Sign in

Bausch & Lomb Corp revenue

Bausch & Lomb Corp's revenue was $5.10bn in fiscal 2025, up 6.5% on the year before. Since fiscal 2020 ($3.41bn) it has grown at a compound 8.4% a year. Over the last twelve months it was $5.42bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue3,4123,7653,7684,1464,7915,1015,418
Growth on the year before—+10.3%+0.1%+10.0%+15.6%+6.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Vision Care $2.9B 57.3% ▲ 6.7%
Pharmaceuticals $1.3B 25.2% ▲ 6.2%
Surgical $894M 17.5% ▲ 6.0%
Products and services
Line of business Revenue Share YoY
Products $5.1B 99.2% ▲ 6.4%
Device Products $1.9B 37.8% ▲ 6.8%
Overthe Counter Products $1.8B 36.1% ▲ 6.4%
Pharmaceutical Products $1.1B 21.3% ▲ 11.6%
Branded and Other Generic Products $243M 4.8% ▼ 13.5%
Other $21M 0.4% ▲ 23.5%
Other Revenues $21M 0.4% ▲ 23.5%
Geography
Region Revenue Share YoY
United States and Puerto Rico $2.5B 49.9% ▲ 5.5%
Other Countries $777M 15.2% ▲ 9.1%
China $358M 7.0% 0.0%
France $246M 4.8% ▲ 8.4%
Japan $186M 3.6% ▲ 3.3%
Germany $164M 3.2% ▲ 7.9%
RU $148M 2.9% ▲ 23.3%
United Kingdom $137M 2.7% ▲ 3.8%
Canada $135M 2.6% ▲ 6.3%
IT $102M 2.0% ▲ 12.1%
ES $101M 2.0% ▲ 9.8%
Mexico $75M 1.5% 0.0%
PL $75M 1.5% ▲ 15.4%
South Korea $51M 1.0% ▲ 8.5%

From Bausch & Lomb Corp's 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bausch & Lomb Corp $5.42bn 8.9% 10.9%
ResMed| $5.73bn 9.0% 9.4%
Dexcom $5.10bn 13.0% 14.5%
Steris $6.04bn 8.4% 9.0%
Idexx Laboratories $4.66bn 11.9% 9.1%
Edwards Lifesciences $6.51bn 14.6% 15.3%

Compare with peers

Head to head: BLCO vs RMDBLCO vs DXCMBLCO vs STEBLCO vs IDXX

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bausch & Lomb Corp's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bausch & Lomb Corp.